1. Home
  2. DRS vs EXEL Comparison

DRS vs EXEL Comparison

Compare DRS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Leonardo DRS Inc.

DRS

Leonardo DRS Inc.

HOLD

Current Price

$33.88

Market Cap

9.7B

Sector

Industrials

ML Signal

HOLD

Logo Exelixis Inc.

EXEL

Exelixis Inc.

HOLD

Current Price

$44.36

Market Cap

11.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRS
EXEL
Founded
1969
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
11.1B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
DRS
EXEL
Price
$33.88
$44.36
Analyst Decision
Strong Buy
Buy
Analyst Count
6
24
Target Price
$46.83
$44.73
AVG Volume (30 Days)
966.0K
2.5M
Earning Date
10-29-2025
11-04-2025
Dividend Yield
1.06%
N/A
EPS Growth
33.93
53.55
EPS
0.99
2.38
Revenue
$3,569,000,000.00
$2,288,218,000.00
Revenue This Year
$11.94
$9.14
Revenue Next Year
$6.66
$12.51
P/E Ratio
$34.27
$18.67
Revenue Growth
12.27
9.93
52 Week Low
$28.17
$31.90
52 Week High
$49.31
$49.62

Technical Indicators

Market Signals
Indicator
DRS
EXEL
Relative Strength Index (RSI) 38.52 63.52
Support Level $32.84 $43.00
Resistance Level $34.86 $44.79
Average True Range (ATR) 0.84 1.03
MACD 0.29 0.06
Stochastic Oscillator 41.09 83.48

Price Performance

Historical Comparison
DRS
EXEL

About DRS Leonardo DRS Inc.

Leonardo DRS Inc is a provider of defense products and technologies that are used across land, air, sea, space, and cyber domains. The company is in the design, development, and manufacture of Advanced sensing, network computing, force protection, and electric power and propulsion technologies and solutions. The company has two segments: Advanced Sensing and Computing, which generates the majority of revenue, and the Integrated Mission Systems segment. The Advanced Sensing and Computing segment is engaged in designing, developing, and manufacturing sensing and network computing technology that enables real-time situational awareness required for enhanced operational decision-making and execution by the customers.

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Share on Social Networks: